The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream
Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain
Intervention: Capsaicin 0.1% (Drug); Placebo (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Mayo Clinic Official(s) and/or principal investigator(s): Peter Dyck, MD, Principal Investigator, Affiliation: Mayo Clinic
Summary
This is a study of epidermal (the outer most layer) nerve fibers (ENFs) in the skin of the
body; counts of which are used to determine a disease of nerves called "small nerve fiber
neuropathy."
Capsaicin is approved by the Food and Drug Administration (FDA) for pain relief. Since 0. 1%
capsaicin is known to cause ablation (removal) of ENFs, this study will test whether such
ablation results in relief of spontaneous pain, touch, or heat-pain.
Clinical Details
Official title: The Effect of Ablation of Epidermal Nerve Fibers Using 0.1% Capsaicin Cream on Spontaneous Cutaneous Burning Pain, Tactile Hyperalgesia, and Thermal Hyperalgesia: A Controlled, Masked Trial With an N of 1
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Primary outcome: Burning pain as measured by a numeric rating scale of 1-10
Secondary outcome: Tactile hyperalgesia as measured with monofilaments A, B, C, (through I), ranging in providing forces -3, -2, -1 (through +5) In gramsThermal hyperalgesia as measured by the heat as pain thermode test using CASE IVc
Detailed description:
On the first day, two areas of the skin of the subject's right abdomen will be marked and
identified as sites A and B. Each day for one week the subject will be asked to grade her
degree of discomfort or pain from 1 to 10 at sites marked A and B every two hours beginning
at 8 a. m. and ending at 10 p. m.
Each day except for Saturday and Sunday touch-pressure sensation will be evaluated using
monofilaments and heat pain sensation at sites A and B. Also evaluated will be touch
pressure pain at each of these sites.
On Thursday of the first week 3 mm punch biopsies of the skin will be obtained from sites A
and B and another 3 mm punch biopsy will be obtained on Thursday of the following week from
sites A and B.
Following the first biopsy, the experimental creams will be applied to sites A and B. One
of the experimental creams contains 0. 1% Capsaisin in a bland cream. The second cream
contains no Capsaisin. 0. 1% Capsaisin is known to destroy the small fibers, especially pain
fibers in the skin. Both the investigators applying the cream and the subject will not
know which experimental cream contains the Capsaisin. The creams will be applied on Thursday
of the first week but only after all testing and skin biopsies have been done. The creams
will be left in place except when testing is being done, and they will not be applied after
the second set of skin biopsies has been obtained.
The creams will be applied by the investigators and by the subject, care being taken so that
the tube marked A is applied to the site marked A, and the tube marked B is applied to the
site marked B. Between application to the two sites, investigators and the subject will use
different gloves and applicators, carefully washing their hands with soap and water between
and after applications.
The subject will be asked not to shower or to immerse herself in water but to use sponge
baths, avoiding the tested areas, so that the cream does not move to other areas.
Eligibility
Minimum age: 39 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- pain syndrome
- must be able to be in study for one week
Exclusion Criteria:
- not able to be in study for one week
Locations and Contacts
Mayo Clinic in Rochester, Rochester, Minnesota 55905, United States
Additional Information
Starting date: June 2013
Last updated: June 19, 2013
|